Details for Patent: 8,776,794
Which drugs does patent 8,776,794 protect, and when does it expire?
Patent 8,776,794 protects INOMAX and is included in one NDA.
Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-five patent family members in thirteen countries.
Summary for Patent: 8,776,794
| Title: | Nitric oxide delivery device |
| Abstract: | A nitric oxide delivery device including a valve assembly, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gases containing nitric oxide are also described. |
| Inventor(s): | Duncan P. Bathe, John Klaus, David Christensen |
| Assignee: | Mallinckrodt Pharma IP Trading DAC , Therakos Inc , Mallinckrodt Critical Care Finance Inc |
| Application Number: | US14/065,951 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,776,794 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent 8,776,794
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ireland | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | DISCN | Yes | No | 8,776,794*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Mallinckrodt Ireland | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | AA | RX | Yes | Yes | 8,776,794*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,776,794
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011328891 | ⤷ Start Trial | |||
| Australia | 2013257484 | ⤷ Start Trial | |||
| Australia | 2015200792 | ⤷ Start Trial | |||
| Australia | 2017204422 | ⤷ Start Trial | |||
| Australia | 2017276262 | ⤷ Start Trial | |||
| Brazil | 112013017498 | ⤷ Start Trial | |||
| Canada | 2779766 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
